Table 2. Univariate analysis of the impact of angiogenic factor on overall survival in MDS patients.

Variable	No. of patients	Overall survivala	P-value
Sex			0.378
Male	143	28.7±5.5
Female	65	62.2±20.2
Age (years)			0.029
<60	83	68.9±23.4
⩾60	125	27.9±4.1
Karyotype			<0.001
Good/intermediate	161	39.2±11.1
Poor	35	9.5±2.2
FAB classification			<0.001
RA/RARS	90	68.9±10.3
RAEB	81	18.3±2.4
RAEB-t	19	14.8±3.2
IPSS			<0.001
Low/INT-1	120	62.2±5.5
INT-2/high	76	14.3±2.4
Ang-1			<0.001
Low	104	63.3±17.8
High	104	20.8±4.5
Ang-2			0.151
Low	104	32±14.4
High	104	29.3±4.1
Tie2			0.344
Low	104	29.3±14.5
High	104	30.4±5.4
VEGF-A			0.860
Low	104	29.3±5.5
High	104	32±12.1
VEGF-C			0.921
Low	104	28.7±8
High	104	32±13.8

Abbreviations: MDS=myelodysplastic syndromes; FAB=French–American–British classification; RA=refractory anaemia; RARS=refractory anaemia with ring sideroblasts; RAEB=refractory anaemia with excess blasts; RAEB-t=refractory anaemia with excess blasts in transformation; IPSS=international prognosis scoring system; INT=intermediate; Ang=angiopoietin; VEGF=vascular endothelial growth factor.

^aMedian (months±s.d.).

Median value of each angiogenic factor was used as the cutoff level to define low- and high-expression groups.